8-K filing — ONCOLYTICS BIOTECH INC (ONCY)
Filed: 2026-09-10 AccNo: 0001129928-26-000055 Size: 161 KB Item 8.01: Other Events
Stocks · News reference
Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oncolytics Biotech Announces Pelareorep Lowered Tumor Growth Compared To Control During Initial Treatment Period
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.